NULL

In its biggest deal in history, AURELIUS acquires McKesson UK

01.11.2021

In its biggest deal in history, AURELIUS acquires McKesson UK

  • AURELIUS agrees to acquire McKesson UK, the UK’s leading fully integrated healthcare provider, across retail, wholesale, homecare and digital platforms for an enterprise value of GBP 387m
  • Represents the largest transaction undertaken by AURELIUS since being established in 2005 and only a few months since the launch of the AURELIUS European Opportunities Fund IV
  • McKesson UK is focused on playing a key role in the UK healthcare market including in the response to the COVID-19 pandemic
  • AURELIUS is committed to supporting McKesson UK with the delivery of its growth initiatives and its next stage of development
  • Co-investment structure together with AURELIUS Equity Opportunities SE & Co. KGaA is already paying off
  • Further enhances AURELIUS’ renowned track record in the industry as carve-out specialist and trusted acquirer

Munich/London, November 1, 2021 – In its largest deal to date, AURELIUS today announces the acquisition of McKesson UK in a corporate carve-out from US healthcare company McKesson Corporation, Irving, Texas. The deal with an enterprise value of GBP 387m will be completed by AURELIUS’ co-investment structure with AURELIUS European Opportunities Fund IV, controlling a 70 % stake, and AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %. The transaction is expected to close in Q1 2022, subject to customary closing conditions, including receipt of required regulatory approvals.

The McKesson UK business has an established position in the healthcare sector, comprising Lloyds Pharmacy as well as wholesale pharmaceuticals distributor, AAH Pharmaceuticals, and generated over GBP 5 billion in revenues and an EBITDA in the high double-digit millions in 2020.

McKesson UK operates four divisions: retail, digital, homecare and wholesale. The business has over 18,000 employees, including pharmacists, nurses, logistics operatives as well as store, warehouse and administration personnel. Thanks to McKesson’s established position in the UK as an integrated player in the healthcare sector and AURELIUS’ proven track record in assisting companies deliver on their growth potential, the company is well-positioned to meet consumer expectations. The business is in a strong financial position, underpinned by long-standing customer relationships and new opportunities such as the provision of additional healthcare services across its pharmacy estate and the ability to facilitate the increasing trend of primary care being delivered digitally to patients at home.

AURELIUS has a strong track record of successful carve-out transactions and operational transformation in the European mid-market. Recent transactions include the successful carve-outs of SSE Contracting, a leading multi-disciplinary mechanical and electrical contracting business, from SSE Plc, and Panasonic Consumer Energy, a leading producer in the European consumer batteries market, from Panasonic Europe B.V.

Dr. Dirk Markus, Founding Partner of AURELIUS, said:

“I am very excited about the transaction which marks a new milestone in the development of AURELIUS, lifting the whole organisation to a new level. This major transaction validates the strategic decision to raise AURELIUS European Opportunities Fund IV. We now have available capital of more than EUR 500m and are looking forward to further exciting opportunities.

I would like to thank McKesson for placing its trust in us. Our agreement with McKesson builds on AURELIUS’ proven track record as a trusted investor in corporate carve-outs, leveraging AURELIUS’ operational expertise to grow portfolio companies. A special thank you also goes to our investment team all of whom played an important role in reaching this stage. I am looking forward to the management and operational team providing their expertise and know-how in supporting the business under new ownership.”

AURELIUS Partner Tristan Nagler said:

“We see significant potential in all four segments of McKesson UK to grow and enhance the business along with delivering further benefits to customers through additional investments – for example in digitalisation measures and other initiatives to further increase the quality and reliability of service for the patients and communities that McKesson UK serves. The transaction with McKesson reaffirms that AURELIUS is well-positioned and well-regarded in the European mid-market as a pan-European asset manager offering sustainable value creation for its stakeholders.”

AURELIUS was advised by Rothschild & Co. (Corporate Finance), PwC and FRP (Financial), Interpath (Tax), Mayer Brown and DLA (Legal), Cardano (Pensions), Kearney (IT) and Mansfield (Commercial).

Legal Information

The information on this website is for informational purposes only. The information on this website is not, and is not intended to be, investment advice nor is it a recommendation to enter into any investment; investors should seek independent investment advice before making any investment decisions. The information on this website does not constitute an offer to buy or sell any investment product or service or to engage in any investment activity, or a solicitation of any investment product or service in any jurisdiction in which Aurelius is not permitted to provide its services or make available any investment product.

Any investment opportunities that Aurelius makes available from time to time will only be available to professional investors and will be subject to separate terms and conditions which will apply. This website and the contents herein are only available to such investors in jurisdictions where Aurelius is permitted to offer its products or services. No other person may rely on the information contained in this website.

For UK recipients

This website has been communicated by Aurelius Investment Advisory Limited (“Aurelius”), an authorised representative for its principal Mirabella Advisers LLP, which is authorized and regulated by the Financial Conduct Authority, FCA FRN 606792.

This website is directed at only those entities who are investment professionals with professional experience in matters relating to the contents of this website or other persons who would be classified as professional investors or eligible counterparties pursuant to the rules of the Financial Conduct Authority. In particular, this website is not available to, and may not be relied on by, any person who is a retail investor. If you are in any doubt as to whether you would be deemed to be a retail investor, please seek professional advice and refrain from accessing this website until such advice has been received.